Companion Diagnostics (CDx) Development Market

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Evolution of Personalized Medicines

5.3. An Overview of Companion Diagnostics
5.3.1. Development of Companion Diagnostics

5.3.2. Analytical Techniques Used in Companion Diagnostic Tests
5.3.2.1. Immunohistochemistry
5.3.2.2. In-situ Hybridization
5.3.2.3. Polymerase Chain Reaction
5.3.2.4. DNA Sequencing / Next Generation Sequencing

5.3.3. Advantages of Companion Diagnostics

5.4. Applications of Companion Diagnostics across Different Therapeutic Areas
5.4.1. Oncological Disorders
5.4.2. Infectious Diseases
5.4.3. Neurological Disorders

5.5. Regulatory Review and Approval Process for Companion Diagnostics
5.6. Existing Challenges and Need for Outsourcing
5.7. Basic Guidelines for Selecting a Contract Diagnostics Organization (CDO)
5.8. Future Perspectives

6. COMPANION DIAGNOSTICS DEVELOPMENT SERVICE PROVIDERS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Companion Diagnostics Development Service Providers: List of Players
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters (Region)
6.2.5. Analysis by Company Ownership
6.2.6. Analysis by Type of Services Offered
6.2.7. Analysis by Type of Affiliated Service Offered
6.2.8. Analysis by AI Support
6.2.9. Analysis by Type of Analytical Techniques Used
6.2.10. Analysis by Target Therapeutic Area
6.2.11. Analysis by Regulatory Accreditation / Certification
6.2.12. Analysis by Type of Services Offered, Company Size and Location of Headquarters (Region)
6.2.13. Analysis by Analytical Technique Used, Company Size and Location of Headquarters (Region)

7. COMPANY COMPETITIVENESS ANALYSIS
7.1 Chapter Overview
7.2 Assumptions and Key Parameters
7.3 Methodology
7.4 Companion Diagnostics Service Providers: Company Competitiveness Analysis
7.4.1 Companion Diagnostics Service Providers based in North America
7.4.2 Companion Diagnostics Service Providers based in Europe
7.4.3 Companion Diagnostics Service Providers based in Asia-Pacific

8. COMPANION DIAGNOSTICS DEVELOPMENT SERVICE PROVIDERS: DETAILED COMPANY PROFILES
8.1. Chapter Overview
8.2. Key Players in North America
8.2.1. Geneuity Clinical Research Services
8.2.1.1. Company Overview
8.2.1.2. Service Portfolio
8.2.1.3. Recent Developments and Future Outlook

8.2.2. Labcorp
8.2.2.1. Company Overview
8.2.2.2. Service Portfolio
8.2.2.3. Recent Developments and Future Outlook

8.2.3. Q² Solutions
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Recent Developments and Future Outlook

8.2.4. Quest Diagnostics
8.2.4.1. Company Overview
8.2.4.2. Service Portfolio
8.2.4.3. Recent Developments and Future Outlook

8.2.5. ResearchDx
8.2.5.1. Company Overview
8.2.5.2. Service Portfolio
8.2.5.3. Recent Developments and Future Outlook

8.3. Key Players in Europe
8.3.1. Almac Diagnostic Services
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.3. Recent Developments and Future Outlook

8.3.2. Eurofins
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.3. Recent Developments and Future Outlook

8.3.3. QIAGEN
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.3. Recent Developments and Future Outlook

8.4. Key Players in Asia-Pacific
8.4.1. BGI Genomics
8.4.1.1. Company Overview
8.4.1.2. Service Portfolio
8.4.1.3. Recent Developments and Future Outlook

8.4.2. MEDICAL & BIOLOGICAL LABORATORIES (MBL)
8.4.2.1. Company Overview
8.4.2.2. Service Portfolio
8.4.2.3. Recent Developments and Future Outlook

9. COMPANION DIAGNOSTICS DEVELOPMENT SERVICE PROVIDERS: SHORT COMPANY PROFILES
9.1. Chapter Overview
9.2. Key Players in North America
9.2.1. Agilent Technologies
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio

9.2.2. Creative Biolabs
9.2.2.1. Company Overview
9.2.2.2. Service Portfolio

9.2.3. ICON Specialty Laboratories
9.2.3.1. Company Overview
9.2.3.2. Service Portfolio

9.2.4. NeoGenomics Laboratories
9.2.4.1. Company Overview
9.2.4.2. Service Portfolio

9.3. Key Players in Europe
9.3.1. Cerba Research
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio

9.3.2. Randox Biosciences
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio

9.3.3. Roche
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio

9.3.4. Siemens Healthineers
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio

9.3.5. Unilabs
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio

9.4. Key Players in Asia-Pacific
9.4.1. Abnova
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio

9.4.2. Celemics
9.4.2.1. Company Overview
9.4.2.2. Service Portfolio

9.4.3. MEDx Translational Medicine
9.4.3.1. Company Overview
9.4.3.2. Service Portfolio

9.4.4. Novogene
9.4.4.1. Company Overview
9.4.4.2. Service Portfolio

9.4.5. Shuwen Biotech
9.4.5.1. Company Overview
9.4.5.2. Service Portfolio

10. COMPANION DIAGNOSTIC PRODUCTS: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Companion Diagnostics: List of Marketed / Investigational Products
10.2.1. Analysis by Type of Sample Used
10.2.2. Analysis by Type of Biomarker Detected
10.2.3. Analysis by Analytical Technique Used
10.2.4. Analysis by Target Disease Indication
10.2.5. Analysis by Target Therapeutic Area
10.2.6. Analysis by Commercial Availability and Target Therapeutic Area
10.2.7. Marketed Products: Analysis by Year of FDA Approval
10.2.8. Marketed Products: Analysis by Year of Other Regulatory Approval
10.2.9. Marketed Products: Analysis by Regulatory Authority Involved
10.2.10. Most Popular Companion Drugs: Analysis by Number of Companion Diagnostic Products

10.3. Companion Diagnostics: List of Developers
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Analysis by Company Ownership
10.3.5. Most Active Players: Analysis by Number of Marketed Products

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Companion Diagnostic Development Service Providers: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Technology
11.3.5. Analysis by Target Therapeutic Area
11.3.6. Analysis by Type of Partner
11.3.7. Analysis by Year of Partnership and Type of Partner
11.3.8. Most Active Players: Analysis by Number of Partnerships

11.3.9. Analysis by Geography
11.3.9.1. Local and International Agreements
11.3.9.2. Intercontinental and Intracontinental Agreements

12. LIKELY PARTNER ANALYSIS
12.1. Chapter Overview
12.2. Scoring Criteria and Key Assumptions
12.3. Scope and Methodology

12.4. Likely Partners for Companion Diagnostics Service Providers: Alzheimer’s Disease
12.4.1. Industry Players Focused on Amyloid Beta Biomarker
12.4.1.1. Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials Sponsored by Industry Players

12.4.2. Non-Industry Players Focused on Amyloid Beta Biomarker
12.4.2.1. Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.4.3. Industry Players Focused on Tau Biomarker
12.4.3.1. Regional Distribution of Tau Biomarker Focused Clinical Trials Sponsored by Industry Players

12.4.4. Non-Industry Players Focused on Tau Biomarker
12.4.4.1. Regional Distribution of Tau Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.5. Likely Partners for Companion Diagnostics Service Providers: Breast Cancer
12.5.1. Industry Players Focused on BRCA Biomarker
12.5.1.1. Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Industry Players

12.5.2. Non-Industry Players Focused on BRCA Biomarker
12.5.2.1. Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.5.3. Industry Players Focused on HER Biomarker
12.5.3.1. Regional Distribution of HER Biomarker Focused Clinical Trials Sponsored by Industry Players

12.5.4. Non-Industry Players Focused on HER Biomarker
12.5.4.1. Regional Distribution of HER Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.5.5. Industry Players Focused on PD-L1 Biomarker
12.5.5.1. Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Industry Players

12.5.6. Non-Industry Players Focused on PD-L1 Biomarker
12.5.6.1. Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.5.7. Industry Players Focused on HR Biomarker
12.5.7.1. Regional Distribution of HR Biomarker Focused Clinical Trials Sponsored by Industry Players

12.5.8. Non-Industry Players Focused on HR Biomarker
12.5.8.1. Regional Distribution of HR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.6. Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer
12.6.1. Industry Players Focused on BRAF Biomarker
12.6.1.1. Regional Distribution of BRAF Biomarker Focused Clinical Trials Sponsored by Industry Players

12.6.2. Non-Industry Players Focused on BRAF Biomarker
12.6.2.1. Regional Distribution of BRAF Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.6.3. Industry Players Focused on EGFR Biomarker
12.6.3.1. Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Industry Players

12.6.4. Non-Industry Players Focused on EGFR Biomarker
12.6.4.1. Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.6.5. Industry Players Focused on KRAS Biomarker
12.6.5.1. Regional Distribution of KRAS Biomarker Focused Clinical Trials Sponsored by Industry Players

12.6.6. Non-Industry Players Focused on KRAS Biomarker
12.6.6.1. Regional Distribution of KRAS Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.6.7. Industry Players Focused on MSI / dMMR Biomarker
12.6.7.1. Regional Distribution of MSI / dMMR Biomarker Focused Clinical Trials Sponsored by Industry Players

12.6.8. Non-Industry Players Focused on MSI / dMMR Biomarker
12.6.8.1. Regional Distribution of MSI / dMMR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.7. Likely Partners for Companion Diagnostic Service Providers: Lung Cancer
12.7.1. Industry Players Focused on ALK Biomarker
12.7.1.1. Regional Distribution of ALK Biomarker Focused Clinical Trials Sponsored by Industry Players

12.7.2. Non-Industry Players Focused on ALK Biomarker
12.7.2.1. Regional Distribution of ALK Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.7.3. Industry Players Focused on AST Biomarker
12.7.3.1. Regional Distribution of AST Biomarker Focused Clinical Trials Sponsored by Industry Players

12.7.4. Non-Industry Players Focused on AST Biomarker
12.7.4.1. Regional Distribution of AST Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.7.5. Industry Players Focused on EGFR Biomarker
12.7.5.1. Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Industry Players

12.7.6. Non-Industry Players Focused on EGFR Biomarker
12.7.6.1. Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.7.7. Industry Players Focused on PD-L1 Biomarker
12.7.7.1. Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Industry Players

12.7.8. Non-Industry Players Focused on PD-L1 Biomarker
12.7.8.1. Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.7.9. Industry Players Focused on RET Biomarker
12.7.9.1. Regional Distribution of RET Biomarker Focused Clinical Trials Sponsored by Industry Players

12.7.10. Non-Industry Players Focused on RET Biomarker
12.7.10.1. Regional Distribution of RET Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.8. Likely Partners for Companion Diagnostics Service Providers: HIV
12.8.1. Industry Players Focused on CCR5 Biomarker
12.8.1.1. Regional Distribution of CCR5 Biomarker Focused Clinical Trials Sponsored by Industry Players
12.8.2. Non-Industry Players Focused on CCR5 Biomarker
12.8.2.1. Regional Distribution of CCR5 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.9. Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer
12.9.1. Industry Players Focused on BRCA Biomarker
12.9.1.1. Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Industry Players

12.9.2. Non-Industry Players Focused on BRCA Biomarker
12.9.2.1. Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.9.3. Industry Players Focused on CA-125 Biomarker
12.9.3.1. Regional Distribution of CA-125 Biomarker Focused Clinical Trials Sponsored by Industry Players

12.9.4. Non-Industry Players Focused on CA-125 Biomarker
12.9.4.1. Regional Distribution of CA-125 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.10. Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer
12.10.1. Industry Players Focused on AR-V7 Biomarker
12.10.1.1. Regional Distribution of AR-V7 Biomarker Focused Clinical Trials Sponsored by Industry Players

12.10.2. Non-Industry Players Focused on AR-V7 Biomarker
12.10.2.1. Regional Distribution of AR-V7 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

12.10.3. Industry Players Focused on PTEN Biomarker
12.10.3.1. Regional Distribution of PTEN Biomarker Focused Clinical Trials Sponsored by Industry Players

12.10.4. Non-Industry Players Focused on PTEN Biomarker
12.10.4.1. Regional Distribution of PTEN Biomarker Focused Clinical Trials Sponsored by Non-Industry Players

13. MERGERS AND ACQUISITONS
13.1. Chapter Overview
13.2. Merger and Acquisition Models

13.3. Companion Diagnostic Development Service Providers: Mergers and Acquisitions
13.3.1. Analysis by Year of Deal
13.3.2. Analysis by Type of Deal

13.3.3. Analysis by Geography
13.3.3.1. Local and International Agreements
13.3.3.2. Intercontinental and Intracontinental Agreements

13.3.4. Ownership Change Matrix
13.3.5. Key Value Drivers of Acquisitions
13.3.6. Key Players: Analysis by Number of Mergers and Acquisitions
13.3.7. Key Acquisitions: Deal Multiples

14. STAKEHOLDER NEEDS ANALYSIS
14.1. Chapter Overview
14.2. Companion Diagnostics: Interests / Needs of Different Stakeholders
14.3. Comparison of Interests / Needs of Various Stakeholders
14.3.1. Interests / Needs of Drug Developers
14.3.2. Interests / Needs of Companion Diagnostics Developers
14.3.3. Interests / Needs of Regulatory Authorities
14.3.4. Interests / Needs of Testing Laboratories
14.3.5. Interests / Needs of Payers / Insurance Providers
14.3.6. Interests / Needs of Physicians
14.3.7. Interests / Needs of Patients

14.4. Overall Summary

15. VALUE CHAIN ANALYSIS
15.1. Chapter Overview
15.2. The Companion Diagnostics Value Chain
15.3. Cost Distribution Across the Value Chain
15.3.1. Cost Associated with Research and Product Development
15.3.2. Cost Associated with Manufacturing and Assembly
15.3.3. Cost Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
15.3.4. Cost Associated with Payer Negotiation and KOL Engagement
15.3.5. Cost Associated with Marketing and Sales

16. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA INITIATIVES
16.1. Chapter Overview
16.2. Methodology
16.3. Clinical Trial Analysis
16.3.1. List of Likely Drug Candidates for IVD Developers

16.4. Cumulative Distribution of Biomarker-based Trials by Registration Year, 2016-2019
16.4.1. Analysis of Biomarker-based Trials of Most Popular Biomarkers
16.4.2. Analysis of Biomarker-based Trials of Moderately Popular Biomarkers
16.4.3. Analysis of Biomarker-based Trials of Less Popular / Preliminary Stage Biomarkers
16.4.4. Word Cloud of Other Emerging Biomarkers
16.4.5. Cumulative Distribution of Trials by Registration Year and Most Popular Biomarkers
16.4.6. Cumulative Distribution of Trials by Registration Year and Moderately Popular Biomarkers
16.4.7. Cumulative Distribution of Trials by Registration Year and Less Popular Biomarkers

16.5. Distribution of Biomarker-based Trials by Most Popular Indications
16.5.1. Distribution of Biomarker-based Trials by Moderately Popular Indications
16.5.2. Distribution of Biomarker-based Trials by Less Popular Other Indications
16.5.3. Word Cloud of Other Emerging Indications in Biomarker-based Clinical Trials
16.5.4. Cumulative Distribution of Trials by Registration Year and Most Popular Indication
16.5.5. Cumulative Distribution of Trials by Registration Year and Moderately Popular Indications
16.5.6. Cumulative Distribution of Trials by Registration Year and Less Popular / Preliminary Stage Indications

16.6. Analysis of Biomarker-based Trials by Phase of Development
16.6.1. Analysis of Biomarker-based Trials by Phase of Development and Most Popular Biomarkers
16.6.2. Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Biomarkers
16.6.3. Analysis of Biomarker-based Trials by Phase of Development and Less Popular Other Biomarkers
16.6.4. Analysis of Biomarker-based Trials by Phase of Development and Most Popular Indications
16.6.5. Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Indications
16.6.6. Analysis of Biomarker-based Trials by Phase of Development and Less Popular Other Indications

16.7. Analysis of Biomarker-based Trials by Sponsor
16.7.1. Analysis of Biomarker-based Trials by Sponsor and Most Popular Biomarkers
16.7.2. Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Biomarkers
16.7.3 Analysis of Biomarker-based Trials by Sponsor and Most Popular Indications
16.7.4. Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Indications

16.8. Analysis of Biomarker-based Trials by Recruitment Status
16.9. Analysis of Biomarker-based Trials by Therapy Design

16.10. Analysis of Biomarker-based Trials by Geography
16.10.1. Analysis of Biomarker-based Trials by Trial Phase and Recruitment Status

16.11. Clinical Trials Summary: Analysis by Biomarker and Most Popular Indications
16.12. Clinical Trials Summary: Analysis by Biomarker and Moderately Popular Indications
16.13. Clinical Trials Summary: Analysis by Biomarker and Preliminary Stage Indications

17. CASE STUDY ON PRECISION MEDICINE SOFTWARE SOLUTIONS
17.1. Chapter Overview
17.2. Precision Medicine Software Solutions: List of Players
17.2.1. Analysis by Year of Establishment
17.2.2. Analysis by Company Size
17.2.3. Analysis by Location of Headquarters (Region)
17.2.4. Analysis by Company Size and Location of Headquarters (Region)

17.3. Precision Medicine Software Solutions: List of Software
17.3.1. Analysis by Status of Development
17.3.2. Analysis by Type of Platform
17.3.3. Analysis by Regulatory Accreditation Received
17.3.4. Analysis by Target Therapeutic Area
17.3.5. Analysis by Type of Data Handled
17.3.6. Analysis by Purpose of Software
17.3.7. Analysis by End-User
17.3.8. Most Active Players: Distribution by Number of Software

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion

19. GLOBAL COMPANION DIAGNOSTICS DEVELOPMENT SERVICES MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Global Companion Diagnostics Development Services Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario

19.4. Key Market Segmentations

20. COMPANION DIAGNOSTICS DEVELOPMENT SERVICES MARKET, BY TYPE OF SERVICE OFFERED
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Feasibility Studies: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.4. Assay Development: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.5. Analytical Validation: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.6. Clinical Validation: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.7. Manufacturing: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.8. Data Triangulation and Validation

21. COMPANION DIAGNOSTICS DEVELOPMENT SERVICES MARKET, BY TYPE OF ANALYTICAL TECHNIQUE USED
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. NGS: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.4. PCR: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.5. IHC: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.6. Flow Cytometry: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.7. Other Analytical Techniques: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.8. Data Triangulation and Validation

22. COMPANION DIAGNOSTICS DEVELOPMENT SERVICES MARKET, BY TARGET THERAPEUTIC AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Oncological Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
22.4. Non-oncological Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
22.5. Data Triangulation and Validation

23. COMPANION DIAGNOSTICS DEVELOPMENT SERVICES MARKET, BY END USER
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Industry Players: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
23.4. Non-Industry Players: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
23.5. Data Triangulation and Validation

24. COMPANION DIAGNOSTICS DEVELOPMENT SERVICES MARKET, BY KEY GEOGRAPHICAL REGIONS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
24.3.1. US: Historical Trends (2019-2023) and Future Estimates (2024-2035)
24.3.2. Canada: Historical Trends (2019-2023) and Future Estimates (2024-2035)

24.4. Europe: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
24.4.1. Germany: Historical Trends (2019-2023) and Future Estimates (2024-2035)
24.4.2. UK: Historical Trends (2019-2023) and Future Estimates (2024-2035)
24.4.3. Belgium: Historical Trends (2019-2023) and Future Estimates (2024-2035)
24.4.4. Switzerland: Historical Trends (2019-2023) and Future Estimates (2024-2035)
24.4.5. Other European Countries: Historical Trends (2019-2023) and Future Estimates (2024-2035)

24.5. Asia-Pacific: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
24.5.1. China: Historical Trends (2019-2023) and Future Estimates (2024-2035)
24.5.2. Other Asia-Pacific Countries: Historical Trends (2019-2023) and Future Estimates (2024-2035)

24.6. Data Triangulation and Validation

25. CONCLUDING REMARKS

26. EXECUTIVE INSIGHTS
26.1. Chapter Overview
26.2. Apollo Hospital Educational and Research Foundation, and Urvogelbio
26.2.1. Company Snapshot
26.2.2. Interview Transcript: M.V. Sasidhar, Chief Scientific Officer (Apollo Hospital Educational and Research Foundation) and Founder (Urvogelbio)

26.3. MEDICAL & BIOLOGICAL LABORATORIES
26.3.1. Company Snapshot
26.3.2. Interview Transcript: Keita Takahashi (Manager of Sales and Marketing Division), Kyoko Fukushima (Manager of Companion Diagnostic Development Services) and Kyo Shirai (Sales and Marketing Division)

26.4. Genomenon
26.4.1. Company Snapshot
26.4.2. Interview Transcript: Mike Klein, Chief Executive Officer; Mark Kiel, Founder and Chief Scientific Officer; and Candace Chapman, Vice President of Marketing

26.5. Tymora Analytical Operations
26.5.1. Company Snapshot
26.5.2. Interview Transcript: Anton Iliuk, President and Chief Technology Officer

26.6. Novodiax
26.6.1. Company Snapshot
26.6.2. Interview Transcript: Paul Kortschak, Former Senior Vice President

26.7. OWL Metabolomics
26.7.1. Company Snapshot
26.7.2. Interview Transcript: Pablo Ortiz, Chief Executive Officer

26.8. NeoGenomics Laboratories
26.8.1. Company Snapshot
26.8.2. Interview Transcript: Lawrence M. Weiss, Former Chief Scientific Officer

27. APPENDIX 1: TABULATED DATA

28. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Overall Market Landscape of Companion Diagnostics Development Service Providers
Figure 4.2 Executive Summary: Market Landscape of Companion Diagnostics Products
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Likely Partner Analysis
Figure 4.5 Executive Summary: Mergers and Acquisitions
Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Personalized Medicine: Evolution, 2012-2023
Figure 5.2 Companion Diagnostics: Role in Clinical Trials
Figure 5.3 Advantages of Companion Diagnostics
Figure 5.4 Failure Rates: Distribution by Type of Drug Class
Figure 5.5 Companion Diagnostics: Existing Challenges and Need for Outsourcing
Figure 5.6 Key Factors to Consider while Selecting a CDO Partner
Figure 6.1 Companion Diagnostics Development Service Providers: Distribution by Year of Establishment
Figure 6.2 Companion Diagnostics Development Service Providers: Distribution by Company Size
Figure 6.3 Companion Diagnostics Development Service Providers: Distribution by Location of Headquarters
Figure 6.4 Companion Diagnostics Development Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.5 Companion Diagnostics Development Service Providers: Distribution by Company Ownership
Figure 6.6 Companion Diagnostics Development Service Providers: Distribution by Type of Services Offered
Figure 6.7 Companion Diagnostics Development Service Providers: Distribution by Type of Affiliated Services Offered
Figure 6.8 Companion Diagnostics Development Service Providers: Distribution by AI Support
Figure 6.9 Companion Diagnostics Development Service Providers: Distribution by Analytical Techniques Used
Figure 6.10 Companion Diagnostics Development Service Providers: Distribution by Target Therapeutic Area
Figure 6.11 Companion Diagnostics Development Service Providers: Distribution by Regulatory Accreditations / Certifications
Figure 6.12 Companion Diagnostics Development Service Providers: Distribution by Type of Services Offered, Company Size and Location of Headquarters (Region)
Figure 6.13 Companion Diagnostics Development Service Providers: Distribution by Analytical Techniques Used, Company Size and Location of Headquarters (Region)
Figure 7.1 Competitiveness Analysis of Companion Diagnostics Development Service Providers Based in North America
Figure 7.2 Competitiveness Analysis of Companion Diagnostics Development Service Providers Based in Europe
Figure 7.3 Competitiveness Analysis of Companion Diagnostics Development Service Providers Based in Asia-Pacific
Figure 10.1 Companion Diagnostics: Distribution by Type of Sample Used
Figure 10.2 Companion Diagnostics: Distribution by Type of Biomarker Detected
Figure 10.3 Companion Diagnostics: Distribution by Analytical Technique Used
Figure 10.4 Companion Diagnostics: Distribution by Target Disease Indication
Figure 10.5 Companion Diagnostics: Distribution by Therapeutic Area
Figure 10.6 Companion Diagnostics: Distribution by Commercial Availability and Therapeutic Area
Figure 10.7 Companion Diagnostics: Distribution by Year of FDA Approval
Figure 10.8 Companion Diagnostics: Distribution by Year of Other Regulatory Approval
Figure 10.9 Companion Diagnostics: Distribution of Regulatory Authority Involved
Figure 10.10 Companion Diagnostics: Most Popular Companion Drugs
Figure 10.11 Companion Diagnostics Developers: Distribution by Year of Establishment
Figure 10.12 Companion Diagnostics Developers: Distribution by Company Size
Figure 10.13 Companion Diagnostics Developers: Distribution by Location of Headquarters
Figure 10.14 Companion Diagnostic Developers: Distribution by Company Ownership
Figure 10.15 Most Active Players: Distribution by Number of Marketed Products
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2023
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Technology
Figure 11.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 11.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.7 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 11.8 Most Active Players: Distribution by Number for Partnerships
Figure 11.9 Partnerships and Collaborations: Local and International Agreements
Figure 11.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Likely Partner Analysis: Distribution of Industry Players Focused on Amyloid Beta Biomarker by Likelihood of Partnership
Figure 12.2 Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.3 Likely Partner Analysis: Distribution of Non-Industry Players Focused on Amyloid Beta Biomarkers by Likelihood of Partnership
Figure 12.4 Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.5 Likely Partner Analysis: Distribution of Industry Players Focused on Tau Biomarker by Likelihood of Partnership
Figure 12.6 Regional Distribution of Tau Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.7 Likely Partner Analysis: Distribution of Non-Industry Players Focused on Tau Biomarkers by Likelihood of Partnership
Figure 12.8 Regional Distribution of Tau Biomarker Focused Clinical Trials Sponsored by Non- Industry Players
Figure 12.9 Likely Partner Analysis: Distribution of Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Figure 12.10 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.11 Likely Partner Analysis: Distribution of Non-Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Figure 12.12 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.13 Likely Partner Analysis: Distribution of Industry Players Focused on HER Biomarker by Likelihood of Partnership
Figure 12.14 Regional Distribution of HER Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.15 Likely Partner Analysis: Distribution of Non-Industry Players Focused on HER Biomarkers by Likelihood of Partnership
Figure 12.16 Regional Distribution of HER Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.17 Likely Partner Analysis: Distribution of Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Figure 12.18 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.19 Likely Partner Analysis: Distribution of Non-Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Figure 12.20 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.21 Likely Partner Analysis: Distribution of Industry Players Focused on HR Biomarker by Likelihood of Partnership
Figure 12.22 Regional Distribution of HR Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.23 Likely Partner Analysis: Distribution of Non-Industry Players Focused on HR Biomarker by Likelihood of Partnership
Figure 12.24 Regional Distribution of HR Biomarker Focused Clinical Trials Sponsored by Non- Industry Players
Figure 12.25 Likely Partner Analysis: Distribution of Industry Players Focused on BRAF Biomarker by Likelihood of Partnership
Figure 12.26 Regional Distribution of BRAF Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.27 Likely Partner Analysis: Distribution of Non-Industry Players Focused on BRAF Biomarker by Likelihood of Partnership
Figure 12.28 Regional Distribution of BRAF Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.29 Likely Partner Analysis: Distribution of Industry Players Focused on EGFR Partnership
Figure 12.30 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.31 Likely Partner Analysis: Distribution of Non-Industry Players Focused on EGFR Biomarker by Likelihood of Partnership
Figure 12.32 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.33 Likely Partner Analysis: Distribution of Industry Players Focused on KRAS Biomarker by Likelihood of Partnership
Figure 12.34 Regional Distribution of KRAS Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.35 Likely Partner Analysis: Distribution of Non-Industry Players Focused on KRAS Biomarker by Likelihood of Partnership
Figure 12.36 Regional Distribution of KRAS Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.37 Likely Partner Analysis: Distribution of Industry Players Focused on MSI / dMMR Biomarker by Likelihood of Partnership
Figure 12.38 Regional Distribution of MSI /dMMR Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.39 Likely Partner Analysis: Distribution of Non-Industry Players Focused on MSI / dMMR Biomarker by Likelihood of Partnership
Figure 12.40 Regional Distribution of MSI /dMMR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.41 Likely Partner Analysis: Distribution of Industry Players Focused on ALK Biomarker by Likelihood of Partnership
Figure 12.42 Regional Distribution of ALK Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.43 Likely Partner Analysis: Distribution of Non-Industry Players Focused on ALK Biomarker by Likelihood of Partnership
Figure 12.44 Regional Distribution of ALK Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.45 Likely Partner Analysis: Distribution of Industry Players Focused on AST Biomarker by Likelihood of Partnership
Figure 12.46 Regional Distribution of AST Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.47 Likely Partner Analysis: Distribution of Non-Industry Players Focused on AST Biomarker by Likelihood of Partnership
Figure 12.48 Regional Distribution of AST Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.49 Likely Partner Analysis: Distribution of Industry Players Focused on EGFR Biomarker by Likelihood of Partnership
Figure 12.50 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.51 Likely Partner Analysis: Distribution of Non-Industry Players Focused on EGFR Biomarker by Likelihood of Partnership
Figure 12.52 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.53 Likely Partner Analysis: Distribution of Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Figure 12.54 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.55 Likely Partner Analysis: Distribution of Non-Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Figure 12.56 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.57 Likely Partner Analysis: Distribution of Industry Players Focused on RET Biomarker by Likelihood of Partnership
Figure 12.58 Regional Distribution of RET Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.59 Likely Partner Analysis: Distribution of Non-Industry Players Focused on RET Biomarker by Likelihood of Partnership
Figure 12.60 Regional Distribution of RET Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.61 Likely Partner Analysis: Distribution of Industry Players Focused on CCR5 Biomarker by Likelihood of Partnership
Figure 12.62 Regional Distribution of CCR5 Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.63 Likely Partner Analysis: Distribution of Non-Industry Players Focused on CCR5 Biomarker by Likelihood of Partnership
Figure 12.64 Regional Distribution of CCR5 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.65 Likely Partner Analysis: Distribution of Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Figure 12.66 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.67 Likely Partner Analysis: Distribution of Non-Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Figure 12.68 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.69 Likely Partner Analysis: Distribution of Industry Players Focused on CA-125 Biomarker by Likelihood of Partnership
Figure 12.70 Regional Distribution of CA-125 Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.71 Likely Partner Analysis: Distribution of Non-Industry Players Focused on CA-125 Biomarker by Likelihood of Partnership
Figure 12.72 Regional Distribution of CA-125 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.73 Likely Partner Analysis: Distribution of Industry Players Focused on AR-V7 Biomarker by Likelihood of Partnership
Figure 12.74 Regional Distribution of AR-V7 Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.75 Regional Distribution of AR-V7 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 12.76 Likely Partner Analysis: Distribution of Industry Players Focused on PTEN Biomarker by Likelihood of Partnership
Figure 12.77 Regional Distribution of PTEN Biomarker Focused Clinical Trials Sponsored by Industry Players
Figure 12.78 Likely Partner Analysis: Distribution of Non-Industry Players Focused on PTEN Biomarker by Likelihood of Partnership
Figure 12.79 Regional Distribution of PTEN Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Figure 13.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2017-2023
Figure 13.2 Mergers and Acquisitions: Distribution by Type of Deal
Figure 13.3 Mergers and Acquisitions: Local and International Agreements
Figure 13.4 Mergers and Acquisitions: Intercontinental and Intracontinental Agreements
Figure 13.5 Acquisitions: Ownership Change Matrix
Figure 13.6 Acquisitions: Distribution by Key Value Drivers
Figure 13.7 Key Players: Distribution by Number of Mergers and Acquisitions
Figure 14.1 Companion Diagnostics: Stakeholder Interests / Needs
Figure 14.2 Interests / Needs of Drug Developers
Figure 14.3 Interests / Needs of Companion Diagnostic Developers
Figure 14.4 Interests / Needs of Regulatory Authorities
Figure 14.5 Interests / Needs of Testing Laboratories
Figure 14.6 Interests / Needs of Payers / Insurance Providers
Figure 14.7 Interests / Needs of Physicians
Figure 14.8 Interests / Needs of Patients
Figure 14.9 Interests / Needs of Companion Diagnostic Developers: Current and Future Relevance
Figure 14.10 Interests / Needs of Drug Developers: Current and Future Relevance
Figure 14.11 Interests / Needs of Regulatory Authorities: Current and Future Relevance
Figure 14.12 Interests / Needs of Testing Laboratories: Current and Future Relevance
Figure 14.13 Interests / Needs of Payers: Current and Future Relevance
Figure 14.14 Interests / Needs of Physicians: Current and Future Relevance
Figure 14.15 Interests / Needs of Patients: Current and Future Relevance
Figure 14.16 Stakeholder Needs Analysis: Overall Summary
Figure 15.1 The Companion Diagnostics Value Chain
Figure 15.2 Cost Distribution Across Value Chain
Figure 15.3 Costs Associated with Research and Product Development
Figure 15.4 Costs Associated with Manufacturing and Assembly
Figure 15.5 Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 15.6 Costs Associated with Payer Negotiation and KoL Engagement
Figure 15.7 Costs Associated with Marketing and Sales
Figure 16.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 16.2 Clinical Trial Analysis: Distribution by Most Popular Biomarkers
Figure 16.3 Clinical Trial Analysis: Distribution by Moderately Popular Biomarkers
Figure 16.4 Clinical Trial Analysis: Distribution by Less Popular / Preliminary Stage Biomarkers
Figure 16.5 Other Emerging Biomarkers: Word Cloud
Figure 16.6 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Figure 16.7 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
Figure 16.8 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
Figure 16.9 Clinical Trial Analysis: Distribution of Trials by Most Popular Indications
Figure 16.10 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications
Figure 16.11 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Indications
Figure 16.12 Less Popular and Other Indications: Word Cloud
Figure 16.13 Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
Figure 16.14 Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
Figure 16.15 Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
Figure 16.16 Clinical Trial Analysis: Distribution by Trial Phase of Development
Figure 16.17 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
Figure 16.18 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
Figure 16.19 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
Figure 16.20 Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
Figure 16.21 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
Figure 16.22 Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
Figure 16.23 Clinical Trial Analysis: Distribution of Trials by Sponsor
Figure 16.24 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Sponsor
Figure 16.25 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Sponsor
Figure 16.26 Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Sponsor
Figure 16.27 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Sponsor
Figure 16.28 Clinical Trial Analysis: Distribution of Trials by Recruitment Status
Figure 16.29 Clinical Trial Analysis: Distribution of Trials by Therapy Design
Figure 16.30 Clinical Trial Analysis: Distribution by Geography
Figure 16.31 Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 16.32 Clinical Trial Analysis: Distribution of Trials of the Lung Cancer by Affiliated Biomarkers
Figure 16.33 Clinical Trial Analysis: Distribution of Trials of the Breast Cancer by Affiliated Biomarkers
Figure 16.34 Clinical Trial Analysis: Distribution of Trials of the Lymphoma by Affiliated Biomarkers
Figure 16.35 Clinical Trial Analysis: Distribution of Trials of the Ovarian Cancer by Affiliated Biomarkers
Figure 16.36 Clinical Trial Analysis: Distribution of Trials of the Prostate Cancer by Affiliated Biomarkers
Figure 16.37 Clinical Trial Analysis: Distribution of Trials of the Melanoma by Affiliated Biomarkers
Figure 16.38 Clinical Trial Analysis: Distribution of Trials of the Colon / Colorectal Cancer by Affiliated Biomarkers
Figure 16.39 Clinical Trial Analysis: Distribution of Trials of the Head and Neck Cancer by Affiliated Biomarkers
Figure 17.1 Precision Medicine Software Developers: Distribution by Year of Establishment
Figure 17.2 Precision Medicine Software Developers: Distribution by Company Size
Figure 17.3 Precision Medicine Software Developers: Distribution by Location of Headquarters (Region)
Figure 17.4 Precision Medicine Software Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 17.5 Precision Medicine Software: Distribution by Status of Development
Figure 17.6 Precision Medicine Software Developers: Distribution by Type of Platform
Figure 17.7 Precision Medicine Software: Distribution by Regulatory Accreditation Received
Figure 17.8 Precision Medicine Software Developers: Distribution by Target Therapeutic Area
Figure 17.9 Precision Medicine Software: Distribution by Status of Development and Target Therapeutic Area
Figure 17.10 Precision Medicine Software Developers: Distribution by Type of Data Handled
Figure 17.11 Precision Medicine Software: Distribution by Status of Development and Type of Data Handled
Figure 17.12 Precision Medicine Software: Distribution by Type of Data Handled and Target Therapeutic Area
Figure 17.13 Precision Medicine Software Developers: Distribution by Purpose of Software
Figure 17.14 Precision Medicine Software: Distribution by End-User
Figure 17.15 Most Active Players: Distribution by Number of Software
Figure 18.1 Market Drivers
Figure 18.2 Market Restraints
Figure 18.3 Market Opportunities
Figure 18.4 Market Challenges
Figure 19.1 Global Companion Diagnostic Development Services Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.2 Global Companion Diagnostic Development Services Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 19.3 Global Companion Diagnostic Development Services Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 20.1 Companion Diagnostic Development Services Market: Distribution by Type of Service Offered, 2019, 2024 and 2035 (USD Billion)
Figure 20.2 Companion Diagnostic Development Services Market for Feasibility Studies, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.3 Companion Diagnostic Development Services Market for Assay Development, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.4 Companion Diagnostic Development Services Market for Analytical Validation, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.5 Companion Diagnostic Development Services Market for Clinical Validation, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.6 Companion Diagnostic Development Services Market for Manufacturing, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.1 Companion Diagnostic Development Services Market: Distribution by Analytical Technique Used, 2019, 2024 and 2035 (USD Billion)
Figure 21.2 Companion Diagnostic Development Services Market for NGS, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.3 Companion Diagnostic Development Services Market for PCR, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.4 Companion Diagnostic Development Services Market for IHC, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.5 Companion Diagnostic Development Services Market for Flow Cytometry, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.6 Companion Diagnostic Development Services Market for Other Analytical Techniques, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.1 Companion Diagnostic Development Services Market: Distribution by Target Therapeutic Area, 2019, 2024 and 2035 (USD Billion)
Figure 22.2 Companion Diagnostic Development Services Market for Oncological Disorders, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.3 Companion Diagnostic Development Services Market for Non-oncological Disorders, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 23.1 Companion Diagnostic Development Services Market: Distribution by End User, 2019, 2024 and 2035 (USD Billion)
Figure 23.2 Companion Diagnostic Development Services Market for Industry Players, Historical Trends (2019-2023) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.3 Companion Diagnostic Development Services Market for Non-Industry Players, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.1 Companion Diagnostic Development Services Market: Distribution by Key Geographical Regions, 2019, 2024 and 2035 (USD Billion)
Figure 24.2 Companion Diagnostic Development Services Market in North America, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.3 Companion Diagnostic Development Services Market in the US, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.4 Companion Diagnostic Development Services Market in Canada, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.5 Companion Diagnostic Development Services Market in Europe, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.6 Companion Diagnostic Development Services Market in Germany, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.7 Companion Diagnostic Development Services Market in the UK, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.8 Companion Diagnostic Development Services Market in Switzerland, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.9 Companion Diagnostic Development Services Market in Belgium, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.10 Companion Diagnostic Development Services Market in Other European Countries, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.11 Companion Diagnostic Development Services Market in Asia-Pacific, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.12 Companion Diagnostic Development Services Market in China, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.13 Companion Diagnostic Development Services Market in Other Asia-Pacific Countries, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 25.1 Concluding Remarks: Market Landscape of Companion Diagnostics Development Service Providers
Figure 25.2 Concluding Remarks: Market Landscape of Companion Diagnostics Products
Figure 25.3 Concluding Remarks: Partnerships and Collaborations
Figure 25.4 Concluding Remarks: Mergers and Acquisitions
Figure 25.5 Concluding Remarks: Market Landscape of Precision Software Applications
Figure 25.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List of Tables

Table 6.1 Companion Diagnostics Service Providers: List of Players
Table 6.2 Companion Diagnostics Development Service Providers: Information on Type of Services Offered
Table 6.3 Companion Diagnostics Development Service Providers: Information on Type of Affiliated Services Offered and AI Support
Table 6.4 Companion Diagnostics Development Service Providers: Information on Analytical Techniques Used
Table 6.5 Companion Diagnostics Development Service Providers: Information on Target Therapeutic Area
Table 6.6 Companion Diagnostics Development Service Providers: Information on Regulatory Certifications / Accreditations
Table 8.1 Companion Diagnostic Development Service Providers: List of Companies Profiled
Table 8.2 Geneuity Clinical Research Services: Company Overview
Table 8.3 Geneuity Clinical Research Services: Service Portfolio
Table 8.4 Labcorp: Company Overview
Table 8.5 Labcorp: Service Portfolio
Table 8.6 Labcorp: Recent Developments and Future Outlook
Table 8.7 Q2 Solutions: Company Overview
Table 8.8 Q2 Solutions: Service Portfolio
Table 8.9 Quest Diagnostics: Company Overview
Table 8.10 Quest Diagnostics: Service Portfolio
Table 8.11 Quest Diagnostics: Recent Developments and Future Outlook
Table 8.12 ResearchDx: Company Overview
Table 8.13 ResearchDx: Service Portfolio
Table 8.14 ResearchDx: Recent Developments and Future Outlook
Table 8.15 Almac Diagnostic Services: Company Overview
Table 8.16 Almac Diagnostic Services: Service Portfolio
Table 8.17 Almac Diagnostic Services: Recent Developments and Future Outlook
Table 8.18 Eurofins: Company Overview
Table 8.19 Eurofins: Service Portfolio
Table 8.20 QIAGEN: Company Overview
Table 8.21 QIAGEN: Service Portfolio
Table 8.22 QIAGEN: Recent Developments and Future Outlook
Table 8.23 BGI Genomics: Company Overview
Table 8.24 BGI Genomics: Service Portfolio
Table 8.25 MEDICAL & BIOLOGICAL LABORATORIES: Company Overview
Table 8.26 MEDICAL & BIOLOGICAL LABORATORIES: Service Portfolio
Table 9.1 Companion Diagnostic Development Service Providers: List of Companies Profiled
Table 9.2 Agilent Technologies: Company Overview
Table 9.3 Agilent Technologies: Service Portfolio
Table 9.4 Creative Biolabs: Company Overview
Table 9.5 Creative Biolabs: Service Portfolio
Table 9.6 ICON Specialty Laboratories: Company Overview
Table 9.7 ICON Specialty Laboratories: Service Portfolio
Table 9.8 NeoGenomics Laboratories: Company Overview
Table 9.9 NeoGenomics Laboratories: Service Portfolio
Table 9.10 Cerba Research: Company Overview
Table 9.11 Cerba Research: Service Portfolio
Table 9.12 Randox Biosciences: Company Overview
Table 9.13 Randox Biosciences: Service Portfolio
Table 9.14 Roche: Company Overview
Table 9.15 Roche: Service Portfolio
Table 9.16 Siemens Healthineers: Company Overview
Table 9.17 Siemens Healthineers: Service Portfolio
Table 9.18 Unilabs: Company Overview
Table 9.19 Unilabs: Service Portfolio
Table 9.20 Abnova: Company Overview
Table 9.21 Abnova: Service Portfolio
Table 9.22 Celemics: Company Overview
Table 9.23 Celemics: Service Portfolio
Table 9.24 MEDx Translational Medicine: Company Overview
Table 9.25 MEDx Translational Medicine: Service Portfolio
Table 9.26 Novogene: Company Overview
Table 9.27 Novogene: Service Portfolio
Table 9.28 Shuwen Biotech: Company Overview
Table 9.29 Shuwen Biotech: Service Portfolio
Table 10.1 Companion Diagnostics: Information on Developer, Sample Used, Type of Biomarker, Analytical Technique Used, Target Disease Indication and Target Therapeutic Area
Table 10.2 Companion Diagnostics: Information on Developer, Commercial Availability, FDA Approval Year, Other Regulatory Approval Year, Companion Drug (Generic Name)
Table 10.3 Companion Diagnostics: List of Developers
Table 11.1 Companion Diagnostics Development Service Providers: List of Partnerships and Collaborations, 2021-2023
Table 12.1 Industry Players Focused on Amyloid Beta Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.2 Non-Industry Players Focused on Amyloid Beta Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.3 Industry Players Focused on Tau Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.4 Non-Industry Players Focused on Tau Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.5 Industry Players Focused on BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.6 Non-Industry Players Focused on BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.7 Industry Players Focused on HER Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.8 Non-Industry Players Focused on HER Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.9 Industry Players Focused on PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.10 Non-Industry Players Focused on PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.11 Industry Players Focused on HR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.12 Non-Industry Players Focused on HR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.13 Industry Players Focused on BRAF Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.14 Non-Industry Players Focused on BRAF Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.15 Industry Players Focused on EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.16 Non-Industry Players Focused on EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.17 Industry Players Focused on KRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.18 Non-Industry Players Focused on KRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.19 Industry Players Focused on MSI / dMMR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.20 Non-Industry Players Focused on MSI / dMMR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.21 Industry Players Focused on ALK Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.22 Non-Industry Players Focused on ALK Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.23 Industry Players Focused on AST Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.24 Non-Industry Players Focused on AST Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.25 Industry Players Focused on EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.26 Non-Industry Players Focused on EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.27 Industry Players Focused on PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.28 Non-Industry Players Focused on PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.29 Industry Players Focused on RET Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.30 Non-Industry Players Focused on RET Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.31 Industry Players Focused on CCR5 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.32 Non-Industry Players Focused on CCR5 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.33 Industry Players Focused on BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.34 Non-Industry Players Focused on BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.35 Industry Players Focused on CA-125 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.36 Non-Industry Players Focused on CA-125 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.37 Industry Players Focused on AR-V7 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.38 Non-Industry Players Focused on AR-V7 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.39 Industry Players Focused on PTEN Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 12.40 Non-Industry Players Focused on PTEN Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 13.1 Companion Diagnostic Development Services: List of Mergers and Acquisitions, 2017-2023
Table 13.2 Acquisitions: Key Value Drivers
Table 13.3 Key Acquisitions: Deal Multiples
Table 14.1 Comparison of Relevance of Interests / Needs of Stakeholders
Table 16.1 List of Likely Drug Candidates / Potential Collaborators for Diagnostic Developers
Table 16.2 List of Biomarkers across Moderately Popular Indications
Table 16.3 List of Biomarkers Across Emerging Indications
Table 17.1 Precision Medicine Software Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 17.2 Precision Medicine Software: Information on Software, Developer, AI Integration, Type of Platform, Regulatory Accreditation and Status of Development
Table 17.3 Precision Medicine Software: Information on Target Therapeutic Area, Purpose of Software and End-User
Table 26.1 Apollo Hospital Educational and Research Foundation, and Urvogelbio: Company Snapshot
Table 26.2 MEDICAL & BIOLOGICAL LABORATORIES: Company Snapshot
Table 26.3 Genomenon: Company Snapshot
Table 26.4 Tymora Analytical Operations: Company Snapshot
Table 26.5 Novodiax: Company Snapshot
Table 26.6 OWL Metabolomics: Company Snapshot
Table 26.7 NeoGenomics Laboratories: Company Snapshot
Table 27.1 Companion Diagnostics Development Service Providers: Distribution by Year of Establishment
Table 27.2 Companion Diagnostics Development Service Providers: Distribution by Company Size
Table 27.3 Companion Diagnostics Development Service Providers: Distribution by Location of Headquarters
Table 27.4 Companion Diagnostics Development Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Table 27.5 Companion Diagnostics Development Service Providers: Distribution by Company Ownership
Table 27.6 Companion Diagnostics Development Service Providers: Distribution by Type of Services Offered
Table 27.7 Companion Diagnostics Development Service Providers: Distribution by Type of Affiliated Services Offered
Table 27.8 Companion Diagnostics Development Service Providers: Distribution by AI Support
Table 27.9 Companion Diagnostics Development Service Providers: Distribution by Analytical Techniques Used
Table 27.10 Companion Diagnostics Development Service Providers: Distribution by Target Therapeutic Area
Table 27.11 Companion Diagnostics Development Service Providers: Distribution by Regulatory Accreditations / Certifications
Table 27.12 Companion Diagnostics: Distribution by Type of Sample Used
Table 27.13 Companion Diagnostics: Distribution by Type of Biomarker Detected
Table 27.14 Companion Diagnostics: Distribution by Analytical Technique Used
Table 27.15 Companion Diagnostics: Distribution by Target Disease Indication
Table 27.16 Companion Diagnostics: Distribution by Target Therapeutic Area
Table 27.17 Companion Diagnostics: Distribution by Commercial Availability and Target Therapeutic Area
Table 27.18 Companion Diagnostics: Distribution by Year of FDA Approval
Table 27.19 Companion Diagnostics: Distribution by Year of Other Regulatory Approval
Table 27.20 Companion Diagnostics: Distribution of Regulatory Authority Involved
Table 27.21 Companion Diagnostics: Most Popular Companion Drugs
Table 27.22 Companion Diagnostics Developers: Distribution by Year of Establishment
Table 27.23 Companion Diagnostics Developers: Distribution by Company Size
Table 27.24 Companion Diagnostics Developers: Distribution by Location of Headquarters
Table 27.25 Companion Diagnostic Developers: Distribution by Company Ownership
Table 27.26 Most Active Players: Distribution by Number of Marketed Products
Table 27.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2023
Table 27.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 27.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Table 27.30 Partnerships and Collaborations: Distribution by Type of Technology
Table 27.31 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 27.32 Partnerships and Collaborations: Distribution by Type of Partner
Table 27.33 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 27.34 Most Active Players: Distribution by Number for Partnerships
Table 27.35 Partnerships and Collaborations: Local and International Agreements
Table 27.36 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 27.37 Likely Partner Analysis: Distribution of Industry Players Focused on Amyloid Beta Biomarker by Likelihood of Partnership
Table 27.38 Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.39 Likely Partner Analysis: Distribution of Non-Industry Players Focused on Amyloid Beta Biomarkers by Likelihood of Partnership
Table 27.40 Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.41 Likely Partner Analysis: Distribution of Industry Players Focused on Tau Biomarker by Likelihood of Partnership
Table 27.42 Regional Distribution of Tau Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.43 Likely Partner Analysis: Distribution of Non-Industry Players Focused on Tau Biomarker by Likelihood of Partnership
Table 27.44 Regional Distribution of Tau Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.45 Likely Partner Analysis: Distribution of Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Table 27.46 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.47 Likely Partner Analysis: Distribution of Non-Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Table 27.48 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.49 Likely Partner Analysis: Distribution of Industry Players Focused on HER Biomarker by Likelihood of Partnership
Table 27.50 Regional Distribution of HER Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.51 Likely Partner Analysis: Distribution of Non-Industry Players Focused on HER Biomarker by Likelihood of Partnership
Table 27.52 Regional Distribution of HER Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.53 Likely Partner Analysis: Distribution of Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Table 27.54 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.55 Likely Partner Analysis: Distribution of Non-Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Table 27.56 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.57 Likely Partner Analysis: Distribution of Industry Players Focused on HR Biomarker by Likelihood of Partnership
Table 27.58 Regional Distribution of HR Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.59 Likely Partner Analysis: Distribution of Non-Industry Players Focused on HR Biomarker by Likelihood of Partnership
Table 27.60 Regional Distribution of HR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.61 Likely Partner Analysis: Distribution of Industry Players Focused on BRAF Biomarker by Likelihood of Partnership
Table 27.62 Regional Distribution of BRAF Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.63 Likely Partner Analysis: Distribution of Non-Industry Players Focused on BRAF Biomarker by Likelihood of Partnership
Table 27.64 Regional Distribution of BRAF Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.65 Likely Partner Analysis: Distribution of Industry Players Focused on EGFR Biomarker by Likelihood of Partnership
Table 27.66 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.67 Likely Partner Analysis: Distribution of Non-Industry Players Focused on EGFR Biomarker by Likelihood of Partnership
Table 27.68 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.69 Likely Partner Analysis: Distribution of Industry Players Focused on KRAS Biomarker by Likelihood of Partnership
Table 27.70 Regional Distribution of KRAS Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.71 Likely Partner Analysis: Distribution of Non-Industry Players Focused on KRAS Biomarker by Likelihood of Partnership
Table 27.72 Regional Distribution of KRAS Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.73 Likely Partner Analysis: Distribution of Industry Players Focused on MSI / dMMR Biomarker by Likelihood of Partnership
Table 27.74 Regional Distribution of MSI / dMMR Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.75 Likely Partner Analysis: Distribution of Industry Players Focused on ALK Biomarker by Likelihood of Partnership
Table 27.76 Regional Distribution of ALK Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.77 Likely Partner Analysis: Distribution of Non-Industry Players Focused on ALK Biomarker by Likelihood of Partnership
Table 27.78 Regional Distribution of ALK Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.79 Likely Partner Analysis: Distribution of Industry Players Focused on AST Biomarker by Likelihood of Partnership
Table 27.80 Regional Distribution of AST Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.81 Likely Partner Analysis: Distribution of Non-Industry Players Focused on AST Biomarker by Likelihood of Partnership
Table 27.82 Regional Distribution of AST Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.83 Likely Partner Analysis: Distribution of Industry Players Focused on EGFR Biomarker by Likelihood of Partnership
Table 27.84 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.85 Likely Partner Analysis: Distribution of Non-Industry Players Focused on EGFR Biomarker by Likelihood of Partnership
Table 27.86 Regional Distribution of EGFR Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.87 Likely Partner Analysis: Distribution of Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Table 27.88 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.89 Likely Partner Analysis: Distribution of Non-Industry Players Focused on PD-L1 Biomarker by Likelihood of Partnership
Table 27.90 Regional Distribution of PD-L1 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.91 Likely Partner Analysis: Distribution of Non-Industry Players Focused on RET Biomarker by Likelihood of Partnership
Table 27.92 Regional Distribution of RET Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.93 Likely Partner Analysis: Distribution of Industry Players Focused on CCR5 Biomarker by Likelihood of Partnership
Table 27.94 Regional Distribution of CCR5 Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.95 Likely Partner Analysis: Distribution of Non-Industry Players Focused on CCR5 Biomarker by Likelihood of Partnership
Table 27.96 Regional Distribution of CCR5 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.97 Likely Partner Analysis: Distribution of Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Table 27.98 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.99 Likely Partner Analysis: Distribution of Non-Industry Players Focused on BRCA Biomarker by Likelihood of Partnership
Table 27.100 Regional Distribution of BRCA Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.101 Likely Partner Analysis: Distribution of Industry Players Focused on CA-125 Biomarker by Likelihood of Partnership
Table 27.102 Regional Distribution of CA-125 Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.103 Likely Partner Analysis: Distribution of Non-Industry Players Focused on CA-125 Biomarker by Likelihood of Partnership
Table 27.104 Regional Distribution of CA-125 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.105 Likely Partner Analysis: Distribution of Industry Players Focused on AR-V7 Biomarker by Likelihood of Partnership
Table 27.106 Regional Distribution of AR-V7 Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.107 Regional Distribution of AR-V7 Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.108 Likely Partner Analysis: Distribution of Industry Players Focused on PTEN Biomarker by Likelihood of Partnership
Table 27.109 Regional Distribution of PTEN Biomarker Focused Clinical Trials Sponsored by Industry Players
Table 27.110 Likely Partner Analysis: Distribution of Non-Industry Players Focused on PTEN Biomarker by Likelihood of Partnership
Table 27.111 Regional Distribution of PTEN Biomarker Focused Clinical Trials Sponsored by Non-Industry Players
Table 27.112 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2017-2023
Table 27.113 Mergers and Acquisitions: Distribution by Type of Deal
Table 27.114 Mergers and Acquisitions: Local and International Agreements
Table 27.115 Mergers and Acquisitions: Intercontinental and Intracontinental Agreements
Table 27.116 Acquisitions: Ownership Change Matrix
Table 27.117 Acquisitions: Distribution by Key Value Drivers
Table 27.118 Key Players: Distribution by Number of Mergers and Acquisitions
Table 27.119 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 27.120 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Table 27.121 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
Table 27.122 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
Table 27.123 Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
Table 27.124 Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
Table 27.125 Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
Table 27.126 Clinical Trial Analysis: Distribution by Trial Phase of Development
Table 27.127 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
Table 27.128 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
Table 27.129 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
Table 27.130 Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
Table 27.131 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
Table 27.132 Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
Table 27.133 Clinical Trial Analysis: Distribution of Trials by Sponsor
Table 27.134 Clinical Trial Analysis: Distribution of Trials by Recruitment Status
Table 27.135 Clinical Trial Analysis: Distribution of Trials by Therapy Design
Table 27.136 Precision Medicine Software Developers: Distribution by Year of Establishment
Table 27.137 Precision Medicine Software Developers: Distribution by Company Size
Table 27.138 Precision Medicine Software Developers: Distribution by Location of Headquarters (Region)
Table 27.139 Precision Medicine Software Developers: Distribution by Location of Headquarters
Table 27.140 Precision Medicine Software Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 27.141 Precision Medicine Software: Distribution by Status of Development
Table 27.142 Precision Medicine Software: Distribution by Status of Development and Location of Developer
Table 27.143 Precision Medicine Software Developers: Distribution by Type of Platform
Table 27.144 Precision Medicine Software: Distribution by Regulatory Accreditation Received
Table 27.145 Precision Medicine Software: Distribution by Target Therapeutic Area
Table 27.146 Precision Medicine Software: Distribution by Status of Development and Target Therapeutic Area
Table 27.147 Precision Medicine Software: Distribution by Type of Data Handled
Table 27.148 Precision Medicine Software: Distribution by Status of Development and Type of Data Handled
Table 27.149 Precision Medicine Software: Distribution by Type of Data Handled and Target Therapeutic Area
Table 27.150 Precision Medicine Software: Distribution by Purpose of Software
Table 27.151 Precision Medicine Software: Distribution by Type of End-User
Table 27.152 Global Companion Diagnostic Development Services Market, Historical Trends (2019-2023) (USD Billion)
Table 27.153 Global Companion Diagnostic Development Services Market, Forecasted Estimates (2024-2035): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 27.154 Companion Diagnostic Development Services Market: Distribution by Type of Service Offered, 2019, 2024 and 2035
Table 27.155 Companion Diagnostic Development Services Market for Feasibility Studies, Historical Trends (2019-2023) (USD Million)
Table 27.156 Companion Diagnostic Development Services Market for Feasibility Studies, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.157 Companion Diagnostic Development Services Market for Assay Development, Historical Trends (2019-2023) (USD Million)
Table 27.158 Companion Diagnostic Development Services Market for Assay Development, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.159 Companion Diagnostic Development Services Market for Analytical Validation, Historical Trends (2019-2023) (USD Million)
Table 27.160 Companion Diagnostic Development Services Market for Analytical Validation, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.161 Companion Diagnostic Development Services Market for Clinical Validation, Historical Trends (2019-2023) (USD Million)
Table 27.162 Companion Diagnostic Development Services Market for Clinical Validation, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.163 Companion Diagnostic Development Services Market for Manufacturing, Historical Trends (2019-2023) (USD Million)
Table 27.164 Companion Diagnostic Development Services Market for Manufacturing, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.165 Companion Diagnostic Development Services Market: Distribution by Analytical Technique Used, 2019, 2024 and 2035
Table 27.166 Companion Diagnostic Development Services Market for NGS, Historical Trends (2019-2023) (USD Million)
Table 27.167 Companion Diagnostic Development Services Market for NGS, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.168 Companion Diagnostic Development Services Market for PCR, Historical Trends (2019-2023) (USD Million)
Table 27.169 Companion Diagnostic Development Services Market for PCR, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.170 Companion Diagnostic Development Services Market for IHC, Historical Trends (2019-2023) (USD Million)
Table 27.171 Companion Diagnostic Development Services Market for IHC, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.172 Companion Diagnostic Development Services Market for Flow Cytometry, Historical Trends (2019-2023) (USD Million)
Table 27.173 Companion Diagnostic Development Services Market for Flow Cytometry, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.174 Companion Diagnostic Development Services Market for Other Analytical Techniques, Historical Trends (2019-2023) (USD Million)
Table 27.175 Companion Diagnostic Development Services Market for Other Analytical Techniques, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.176 Companion Diagnostic Development Services Market: Distribution by Target Therapeutic Area, 2019, 2024 and 2035
Table 27.177 Companion Diagnostic Development Services Market for Oncological Disorders, Historical Trends (2019-2023) (USD Million)
Table 27.178 Companion Diagnostic Development Services Market for Oncological Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.179 Companion Diagnostic Development Services Market for Non-oncological Disorders, Historical Trends (2019-2023) (USD Million)
Table 27.180 Companion Diagnostic Development Services Market for Non-oncological Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.181 Companion Diagnostic Development Services Market: Distribution by End User, 2019, 2024 and 2035
Table 27.182 Companion Diagnostic Development Services Market for Industry Players, Historical Trends (2019-2023) (USD Million)
Table 27.183 Companion Diagnostic Development Services Market for Industry Players, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.184 Companion Diagnostic Development Services Market for Non-Industry Players, Historical Trends (2019-2023) (USD Million)
Table 27.185 Companion Diagnostic Development Services Market for Non-Industry Players, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.186 Companion Diagnostic Development Services Market: Distribution by Key Geographical Regions, 2019, 2024 and 2035
Table 27.187 Companion Diagnostic Development Services Market in North America, Historical Trends (2019-2023) (USD Million)
Table 27.188 Companion Diagnostic Development Services Market in North America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.189 Companion Diagnostic Development Services Market in the US, Historical Trends (2019-2023) (USD Million)
Table 27.190 Companion Diagnostic Development Services Market in the US, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.191 Companion Diagnostic Development Services Market in Canada, Historical Trends (2019-2023) (USD Million)
Table 27.192 Companion Diagnostic Development Services Market in Canada, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.193 Companion Diagnostic Development Services Market in Europe, Historical Trends (2019-2023) (USD Million)
Table 27.194 Companion Diagnostic Development Services Market in Europe, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.195 Companion Diagnostic Development Services Market in Germany, Historical Trends (2019-2023) (USD Million)
Table 27.196 Companion Diagnostic Development Services Market in Germany, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.197 Companion Diagnostic Development Services Market in the UK, Historical Trends (2019-2023) (USD Million)
Table 27.198 Companion Diagnostic Development Services Market in the UK, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.199 Companion Diagnostic Development Services Market in Switzerland, Historical Trends (2019-2023) (USD Million)
Table 27.200 Companion Diagnostic Development Services Market in Switzerland, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.201 Companion Diagnostic Development Services Market in Belgium, Historical Trends (2019-2023) (USD Million)
Table 27.202 Companion Diagnostic Development Services Market in Belgium, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.203 Companion Diagnostic Development Services Market in Other European Countries, Historical Trends (2019-2023) (USD Million)
Table 27.204 Companion Diagnostic Development Services Market in Other European Countries, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.205 Companion Diagnostic Development Services Market in Asia-Pacific, Historical Trends (2019-2023) (USD Million)
Table 27.206 Companion Diagnostic Development Services Market in Asia-Pacific, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.207 Companion Diagnostic Development Services Market in China, Historical Trends (2019-2023) (USD Million)
Table 27.208 Companion Diagnostic Development Services Market in China, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.209 Companion Diagnostic Development Services Market in Other Asia-Pacific Countries, Historical Trends (2019-2023) (USD Million)
Table 27.210 Companion Diagnostic Development Services Market in Other Asia-Pacific Countries, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)

List of Companies And Organizations

Please reach out to our team for the details.